Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Urinary tract bacteria" refers to a heterogenous group of bacteria—primarily uropathogenic *Escherichia coli*, but also including *Klebsiella pneumoniae*, *Proteus mirabilis*, *Enterococcus faecalis*, and others—that invade the urinary tract and are responsible for urinary tract infections. They employ a variety of virulence factors, such as fimbrial adhesins and toxins, to colonize host tissues, evade immunity, and persist, frequently forming biofilms particularly in the context of catheters. Choice of therapy is complicated by increasing antibiotic resistance, especially among Gram-negative uropathogens. The term does not refer to a single molecular entity and thus is not a molecular drug target in the conventional sense.
Inhibition of bacterial cell wall synthesis (beta-lactams, cephalosporins, carbapenems); Inhibition of protein synthesis (aminoglycosides); Inhibition of DNA gyrase/topoisomerase (fluoroquinolones); Inhibition of folic acid metabolism (trimethoprim-sulfamethoxazole); Inhibition of cell wall enolpyruvate transferase (fosfomycin)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on null.